Terns Pharmaceuticals, Inc. (TERN)
NASDAQ: TERN · Real-Time Price · USD
45.29
+1.00 (2.26%)
At close: Mar 10, 2026, 4:00 PM EDT
45.09
-0.20 (-0.43%)
After-hours: Mar 10, 2026, 5:14 PM EDT
Terns Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
59
Market Cap
4.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.00M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caris Life Sciences | 812.03M |
| Amicus Therapeutics | 634.21M |
| TG Therapeutics | 616.29M |
| Mirum Pharmaceuticals | 521.31M |
| Xenon Pharmaceuticals | 7.50M |
| CG Oncology | 4.04M |
TERN News
- 13 days ago - Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 5 weeks ago - Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 6 weeks ago - These 20 stocks are strong choices for momentum investors - Market Watch
- 2 months ago - Terns Pharmaceuticals, Inc. (TERN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Terns Announces Pricing of Upsized $650 Million Public Offering - GlobeNewsWire
- 3 months ago - Cancer Study Buoys These Small Biotechs - Barrons